Search

Displaying results 9701 - 9710 of 10000 in total
  1. Drug

    Monoxerutin

    go.drugbank.com/drugs/DB13764
    Experimental

    Monoxerutin is a flavonol, a type of flavonoid.

  2. Drug

    Xamoterol

    go.drugbank.com/drugs/DB13781
    Approved

    Xamoterol is a β1-adrenoceptor partial agonist that has shown to improve systolic and diastolic function in studies with heart failure patients.

  3. Drug

    Reposal

    go.drugbank.com/drugs/DB13805
    Experimental

    Reposal is a barbiturate derivative invented in the 1960s in Denmark that has sedative, hypnotic and anticonvulsant properties. It was used primarily in the treatment of insomnia.

  4. Drug

    Etofylline nicotinate

    go.drugbank.com/drugs/DB13842
    Experimental

    Etofylline nicotinate, a theophylline derivative, is a drug that causes vasodilation and relaxation of smooth muscle.

  5. Drug

    Toyocamycin

    go.drugbank.com/drugs/DB13916
    Experimental

    It is an analog of adenosine, blocks RNA synthesis and ribosome function, and is used mainly as a tool in biochemistry.

  6. Drug

    AC-262536

    go.drugbank.com/drugs/DB13935
    Experimental

    A selective androgen receptor modulator.

  7. Drug

    JNJ-28330835

    go.drugbank.com/drugs/DB13936
    Experimental

    A selective androgen receptor modulator with minimal prostate hypertrophic activity, enhances lean body mass in male rats and stimulates sexual behavior in female rats.

  8. Drug

    Trestolone acetate

    go.drugbank.com/drugs/DB13958
    Experimental

    Trestolone acetate is a synthetic and injected anabolic–androgenic steroid (AAS) and a derivative of nandrolone (19-nortestosterone) which was never marketed.

  9. Drug

    AZD-7325

    go.drugbank.com/drugs/DB13994
    Investigational

    AZD7325 is a high affinity, selective modulator of the GABAA receptor system. [L2936]

  10. Drug

    PZM21

    go.drugbank.com/drugs/DB14030
    Experimental

    PZM21 is a novel μ-opioid receptor (MOPr) ligand that has been reported to induce minimal arrestin recruitment and be devoid of the respiratory depressant effects characteristic of classical μ-opioid ligands